MedTrace Logo

Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients

NCT03015168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117

Last updated 2017-01-09

No results posted yet for this study

Summary

We explored the relationship between NLR and grade 3 or higher treatment related small bowel toxicity and treatment outcome of patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy (IMRT).

Conditions

Interventions

RADIATION

capecitabine and concurrent intensity modulated radiotherapy

patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy

Sponsors & Collaborators

  • General Hospital of Ningxia Medical University

    lead OTHER

Principal Investigators

  • Yan-Yang Wang, M.D. · General Hospital of Ningxia Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03015168 on ClinicalTrials.gov